TABLE 3.
Univariate and multivariate analyses of the association between various parameters and overall survival
| Parameters | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Sex (female/male) | 1.47 (0.72‐3.0) | .28 | ‐ | |
| Age (≥70/<70) | 0.86 (0.42‐1.76) | .692 | ‐ | |
| TNM stage (0, I, II/III, IV) | 4.66 (1.93‐11.2) | <.001* | 4.02 (1.34‐12.0) | .012* |
| Lymphatic invasion (negative/positive) | 4.06 (0.97‐16.9) | .054 | 0.89 (0.15‐5.31) | .903 |
| Venous invasion (negative/positive) | 2.37 (1.11‐5.04) | .025* | 2.12 (0.94‐4.77) | .06 |
| Histological differentiation (well/others) | 1.50 (0.68‐3.31) | .305 | ‐ | |
| Tumoral LOX‐1 score (H/L) | 1.20 (0.62‐2.34) | .574 | ‐ | |
| Stromal LOX‐1 (H/L) | 2.21 (1.10‐4.44) | .024* | ‐ | |
| CD8+ CTL (H/L) | 2.38 (1.17‐4.83) | .016* | ‐ | |
| Stromal LOX‐1/CD8 + CTL | ||||
| H/H | Reference | Reference | ||
| H/L | 5.24 (1.14‐23.9) | .032* | 4.06 (0.88‐18.5) | .07 |
| L/H | 5.0 (1.08‐23.1) | .039* | 6.58 (1.39‐31.0) | .017* |
| L/L | 8.73 (1.99‐38.2) | .004* | 8.55 (1.92–37.9) | .004* |
Abbreviations: CI, confidence interval; HR, hazard ratio; tumoral LOX‐1 score‐L, 0‐3; tumoral LOX‐1 score‐H, 4; stromal LOX‐1‐L, ≤534.4/mm2; stromal LOX‐1‐H, >534.4/mm2; CD8+ CTL‐L, ≤103.4/mm2; CD8+ CTL‐H, >103.4/mm2.
*
P < .05 is considered significant.